Reprieve Cardiovascular, Inc

Irvine, California

Phase III

What changed

Phase III trial registered: Fluid Management of Acute Decompensated Heart Failure Subjects Treated With Reprieve System (FASTR-II) (IDE-G210258)

7mo agoTrial registeredNov 26, 2025Source filing (opens the source filing in a new tab)

Momentum

57no change

Some recent activity, at a steady rate.

Runway (estimate)

—unknown

No disclosed raise on file, so there is nothing to model from.

Stage

Phase III

The furthest-along thing in the public record. Not a projection.

Runway is an estimate: the last disclosed raise (SEC Form D) minus a modeled burn rate for the company’s stage and therapeutic area. It is not a disclosure, and companies routinely raise non-dilutive money we can’t see. How this is calculated.

Grant to raise

Every record Biodatica has resolved onto this company, newest first, each linked to the filing it came from. Where a source publishes no stable deep link for a record, the identifier is shown so you can look it up yourself.

Trial
PHASE3 registered
Jul 14, 2025
Acute Decompensated Heart Failure · RECRUITING · sponsor: Reprieve Cardiovascular, Inc · Fluid Management of Acute Decompensated Heart Failure Subjects Treated With Reprieve System (FASTR-II) (IDE-G210258)
ClinicalTrials.gov · NCT06898515 (opens the source filing in a new tab)
Grant
R01 · $295k · non-dilutive
Feb 1, 2025
UNIVERSITY OF FLORIDA · PI BUTLER, JASON MATHEW · NHLBI · award ends Nov 30, 2027 · Netrin-1 promotes the expansion and function of human hematopoietic stem cells by supporting a pro-hematopoietic vascular niche
NIH RePORTER · NIH RePORTER 11027115 (opens the source filing in a new tab)
Grant
R01 · $633k · non-dilutive
Jul 1, 2023
UNIVERSITY OF FLORIDA · PI BUTLER, JASON MATHEW · NHLBI · award ends May 31, 2027 · Preserving bone marrow niche integrity and function to rejuvenate aged hematopoietic stem cells
NIH RePORTER · NIH RePORTER 11087651 (opens the source filing in a new tab)

How this crosswalk was built

Confidence 100%Edges merged automatically, not yet reviewed by a human

Shared principal investigator or founder links the grant record at 0.75{"reasons":["principal investigator BUTLER, JASON MATHEW is named on this company's filings"]}
Shared principal investigator or founder links the grant record at 0.75{"reasons":["grant to an academic institution linked by a shared principal investigator"]}
new_entity links the trial record at 0.25{"reasons":["no candidate cleared the review threshold"]}

Links score at or above 0.86 to merge automatically. Anything below that and above the review line goes to a human queue. Resolution is a judgment, and it can be wrong. How resolution works.

Event stream

Every scored event, newest first. This is what momentum is computed from.

Phase III trial registered: Fluid Management of Acute Decompensated Heart Failure Subjects Treated With Reprieve System (FASTR-II) (IDE-G210258)
7mo agoTrial registeredSource (opens the source filing in a new tab)
Trial now recruiting: Fluid Management of Acute Decompensated Heart Failure Subjects Treated With Reprieve System (FASTR-II) (IDE-G210258)
7mo agoTrial recruitingSource (opens the source filing in a new tab)
NIH R01 · $0.6M · Preserving bone marrow niche integrity and function to rejuvenate aged hematopoietic stem cells
May 2025Grant renewalSource (opens the source filing in a new tab)

Last disclosed raise

No Form D is on file, so there is no raise to model a runway from. That is why the runway reads “—” rather than a number. It does not mean the company has no money: grants, revenue and notes below the Form D threshold are all invisible here.

Something wrong on this page? The crosswalk is a judgment and we would rather hear it. Report a bad link.

Biodatica publishes impersonal research shown identically to every subscriber. This dossier is informational only, it is not investment advice, and the momentum and runway figures are estimates derived from public filings. The underlying records are U.S. government works. Disclosures · Data sources

Grant to raise

PHASE3 registered

R01 · $295k · non-dilutive

R01 · $633k · non-dilutive